Clinical Trial

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Study acronym: CAPSTONE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-05-12; most recent amendment 2024-09-26.
Status change: Not Yet Recruiting → Recruiting 2022-10-19
Trial Details
NCT Number NCT04888429
Lead Sponsor Qian Chu
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Sarcomatoid Carcinoma of Lung
Enrollment 28 participants
Start Date 2021-07-19
Primary Completion 2024-12-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-01